Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.628 USD | -1.88% | +14.14% | +21.49% |
May. 09 | Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q1 Revenue $27.4M | MT |
Apr. 01 | Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.49% | 77.07M | |
+7.65% | 113B | |
+10.96% | 106B | |
+0.41% | 22.27B | |
-11.98% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.83% | 17.24B | |
+7.01% | 14.29B | |
+35.27% | 12.52B |
- Stock Market
- Equities
- ATRA Stock
- News Atara Biotherapeutics, Inc.
- Atara Says ATA3219 IND Application Approved by FDA for Lupus Nephritis CAR T-Cell Therapy